CN102552479A - 一种用于治疗糖尿病足的中药组合物 - Google Patents
一种用于治疗糖尿病足的中药组合物 Download PDFInfo
- Publication number
- CN102552479A CN102552479A CN2012100173514A CN201210017351A CN102552479A CN 102552479 A CN102552479 A CN 102552479A CN 2012100173514 A CN2012100173514 A CN 2012100173514A CN 201210017351 A CN201210017351 A CN 201210017351A CN 102552479 A CN102552479 A CN 102552479A
- Authority
- CN
- China
- Prior art keywords
- medicine composition
- parts
- chinese medicine
- foot
- diabetic foot
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000008960 Diabetic foot Diseases 0.000 title claims abstract description 31
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 241000411851 herbal medicine Species 0.000 title abstract 4
- 239000003814 drug Substances 0.000 claims abstract description 45
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 20
- 229940079593 drug Drugs 0.000 claims abstract description 15
- 241000131808 Scolopendra Species 0.000 claims description 19
- 241000628997 Flos Species 0.000 claims description 17
- 210000000582 semen Anatomy 0.000 claims description 16
- 241000283956 Manis Species 0.000 claims description 14
- 241000522620 Scorpio Species 0.000 claims description 12
- 239000009490 scorpio Substances 0.000 claims description 12
- 238000005303 weighing Methods 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 9
- 210000003101 oviduct Anatomy 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 241000349731 Afzelia bipindensis Species 0.000 claims description 7
- 229940099259 vaseline Drugs 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 21
- 201000001119 neuropathy Diseases 0.000 abstract description 14
- 208000033808 peripheral neuropathy Diseases 0.000 abstract description 14
- 239000008280 blood Substances 0.000 abstract description 13
- 210000004369 blood Anatomy 0.000 abstract description 13
- 208000025865 Ulcer Diseases 0.000 abstract description 11
- 208000028867 ischemia Diseases 0.000 abstract description 11
- 231100000397 ulcer Toxicity 0.000 abstract description 11
- 208000002193 Pain Diseases 0.000 abstract description 9
- 230000001737 promoting effect Effects 0.000 abstract description 9
- 230000017531 blood circulation Effects 0.000 abstract description 8
- 206010017711 Gangrene Diseases 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 239000002994 raw material Substances 0.000 abstract description 6
- 206010061159 Foot deformity Diseases 0.000 abstract description 5
- 230000008961 swelling Effects 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 5
- 238000010792 warming Methods 0.000 abstract description 4
- 230000003213 activating effect Effects 0.000 abstract description 2
- 208000015181 infectious disease Diseases 0.000 abstract description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 241000258920 Chilopoda Species 0.000 abstract 1
- 241000729173 Cirsium japonicum Species 0.000 abstract 1
- 241000283966 Pholidota <mammal> Species 0.000 abstract 1
- 240000004064 Poterium sanguisorba Species 0.000 abstract 1
- 235000008291 Poterium sanguisorba Nutrition 0.000 abstract 1
- 241000842539 Rhagades Species 0.000 abstract 1
- 240000000528 Ricinus communis Species 0.000 abstract 1
- 235000004443 Ricinus communis Nutrition 0.000 abstract 1
- 235000008282 Sanguisorba officinalis Nutrition 0.000 abstract 1
- 241000239226 Scorpiones Species 0.000 abstract 1
- 206010040849 Skin fissures Diseases 0.000 abstract 1
- 210000001367 artery Anatomy 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 230000003179 granulation Effects 0.000 abstract 1
- 238000005469 granulation Methods 0.000 abstract 1
- HTUMBQDCCIXGCV-UHFFFAOYSA-N lead oxide Chemical compound [O-2].[Pb+2] HTUMBQDCCIXGCV-UHFFFAOYSA-N 0.000 abstract 1
- 201000000585 muscular atrophy Diseases 0.000 abstract 1
- 230000001338 necrotic effect Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 229940126673 western medicines Drugs 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 description 13
- 231100000614 poison Toxicity 0.000 description 10
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 6
- 239000003440 toxic substance Substances 0.000 description 5
- 206010028851 Necrosis Diseases 0.000 description 4
- 238000002266 amputation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000007096 poisonous effect Effects 0.000 description 3
- 206010040872 skin infection Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 2
- 241000717739 Boswellia sacra Species 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 241001489978 Eupolyphaga Species 0.000 description 2
- 239000004863 Frankincense Substances 0.000 description 2
- 241000237903 Hirudo Species 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 210000002469 basement membrane Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 206010062198 microangiopathy Diseases 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000002048 spasmolytic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- WTQYWNWRJNXDEG-UHFFFAOYSA-N 6-Hydroxy-hyoscyamin Natural products CN1C(C2)CC(O)C1CC2OC(=O)C(CO)C1=CC=CC=C1 WTQYWNWRJNXDEG-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012665 Diabetic gangrene Diseases 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- 208000003790 Foot Ulcer Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- WTQYWNWRJNXDEG-LEOABGAYSA-N anisodamine Chemical compound C1([C@@H](CO)C(=O)O[C@@H]2C[C@H]3[C@@H](O)C[C@@H](C2)N3C)=CC=CC=C1 WTQYWNWRJNXDEG-LEOABGAYSA-N 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 238000004070 electrodeposition Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000008899 fufang danshen Substances 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000009561 tongxinluo Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/646—Arachnids, e.g. spiders, scorpions, ticks or mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/648—Myriapods, e.g. centipedes or millipedes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/739—Sanguisorba (burnet)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Insects & Arthropods (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种用于治疗糖尿病足的中药组合物,其原料药的重量份为:全蝎1-30份,密陀僧1-30份,蜈蚣1-30份,冰片1-20份,大蓟1-20份,穿山甲1-20份,蓖麻子1-20份,地榆1-20份,红花1-20份。本发明原料易得且成本低,通过各味药材协同发挥清热解毒、祛腐生肌、活血化瘀、温经通络、消肿止痛的作用,用于治疗神经病变型、动脉缺血型、混合型糖尿病足,症见足部肌肉萎缩,足畸形,足部皮肤感染化脓、皲裂、溃疡,指端溃疡、坏疽,标本兼治,且无毒副作用,患者使用后不易复发,避免了西药治疗糖尿病足产生的副作用。
Description
技术领域
本发明涉及一种用于治疗糖尿病足的中药组合物,属于中药领域。
背景技术
糖尿病足(diabetic foot,DF)是指糖尿病患者由于合并神经病变及各种不同程度末梢血管病变而导致下肢感染、溃疡形成和(或)深部组织的破坏。在临床上,由于糖尿病患者长期受到高血糖的影响,下肢血管硬化、血管壁增厚、弹性下降,血管容易形成血栓,并集结成斑块,而造成下肢血管闭塞、支端神经损伤,从而造成下肢组织病变。而“足”离心脏最远,闭塞现象最严重,从而引发水肿、发黑、腐烂、坏死,形成脱疽,是糖尿病慢性并发症之一,也是导致糖尿病病人致残死亡的主要原因之一。主要临床表现为足部溃疡和坏疽,严重者需要截肢,截肢率高达40%。中国国内糖尿病病人并发足坏疽的约占0.9%~1.7%,60岁以上的老年病人并发糖尿病足坏疽的占2.8%~14.5%,国内本病的截肢率21%~66%。
糖尿病足临床上分为神经病变型、动脉缺血型、混合型(即神经病变和动脉缺血同时存在)。
糖尿病足的溃疡及坏疽的高危险因素有周围血管神经病变、植物神经病变、保护觉丧失、微血管病变、代谢因素、以往有足溃疡史、足畸形、有胼胝、失明及视力严重减退、合并肾脏病变、老年人、糖尿病认知力差等,对于这些高危险因素的防治相当重要;老年缺血性糖尿病足的发生尤为多见,主要是周围血管神经病变所致;毛细血管基底膜增厚是由于血管管腔狭窄,内膜粗糙,血管弹力和收缩力降低,血流不畅,致组织缺血缺氧,红细胞变形性差、血液流变学异常,血管内皮损伤等因素易引起毛细血管基底膜增厚,并有透明样物质沉积,从而引起微血管病变压,糖尿病患者由于血管病变,引起神经营养障碍和缺血性神经炎。
糖尿病足属中医“脱疽”范畴,祖国医学认为糖尿病足的核心病因是气虚阳衰寒凝、气虚不能帅血、阳衰不能温煦、寒凝则血液瘀滞不行、久之则肢端坏死而成脱疽。
目前,用于治疗糖尿病足的药物主要有:1、改善微循环治疗,主要有山莨菪碱、前列素E1、中药制剂复方丹参注射液等;2、降低血液凝固性,主要有潘生丁、阿司匹林、华法林、培达等;3、抗感染治疗,主要应用广谱抗生素和甲硝唑等;4、改善神经病变药物,如依帕斯他等。上述药物只能辅助治疗糖尿病足,不能治标,且副作用大,易引发其他并发症。
中国专利文献CN101757152A公开了一种用于治疗缺血性糖尿病足的中药组合物,由人参、水蛭、土鳖虫、乳香、赤芍、降香、檀香、全蝎、蝉蜕、蜈蚣、冰片、酸枣仁组成,具有益气活血、化瘀通络的功效,该组合物商品名称为通心络胶囊,用于冠心病心绞痛属心气虚乏、血瘀络阻证,虽对缺血性糖尿病足有一定疗效,但起效慢,且对神经病变型和混合型糖尿病足无效。
发明内容
本发明所要解决的技术问题是现有技术中用于治疗糖尿病足的中药组合物起效慢,对神经病变型、动脉缺血型、混合型糖尿病足无效的问题,提供一种起效快,对神经病变型、动脉缺血型、混合型糖尿病足都有疗效的中药组合物及其制备方法。
本发明提供了一种用于治疗糖尿病足的中药组合物,该组合物原料药的重量份为:全蝎1-30份,密陀僧1-30份,蜈蚣1-30份,冰片1-20份,大蓟1-20份,穿山甲1-20份,蓖麻子1-20份,地榆1-20份,红花1-20份。
优选的本发明中药组合物原料药的重量份为:全蝎2-20份,密陀僧2-20份,蜈蚣2-20份,冰片2-10份,大蓟2-10份,穿山甲2-10份,蓖麻子2-10份,地榆2-10份,红花2-10份。
最佳的本发明中药组合物原料药的重量份为:全蝎1份,密陀僧1份,蜈蚣1份,冰片1份,大蓟1份,穿山甲1份,蓖麻子1份,地榆1份,红花1份。
本发明的中药组合物可制成丸剂、片剂、胶囊剂、糖浆剂、颗粒剂、膏剂。
所述中药组合物制成膏剂时所选用的基质是蛤蟆油、凡士林、獾油中的一种或多种。
本发明中药组合物的制备方法,包括如下步骤:
包括如下步骤:
a)称取特定重量份的各原料药待用;
b)将全蝎、密陀僧、蜈蚣、冰片、大蓟、穿山甲、蓖麻子、地榆、红花分别粉碎,研成粉末;
c)将上述粉末混合,加入蛤蟆油、凡士林、獾油中的一种或多种,搅拌均匀即得外用膏剂。
本发明还涉及该中药组合物在制备治疗糖尿病足药物中的用途。
中医治疗糖尿病足的原则及方法主要有清热解毒、祛腐生肌、活血化瘀、温经通络、消肿止痛。
全蝎性平,味辛,有毒,归肝经,具息风镇痉,攻毒散结,通络止痛之功效,列为君药;密陀僧性平,味辛咸,有毒,入足厥阴肝经,具燥湿、解毒、收敛、防腐功效;蜈蚣性温,味辛咸,有毒,归肝脾肺经,具息风镇痉、攻毒散结、通络止痛之功效;与密陀僧相伍,增强清热解毒、通络止痛之功效,共为臣药。
大蓟性凉,味甘苦,归心、肝经,具散瘀、解毒、消痈之功效;穿山甲性微寒,味咸,具活血散结,消痈溃坚之功效;蓖麻子性平,味甘辛,归大肠、肺经,具消肿拔毒、泻下通滞之功效;地榆性寒,味苦酸,归肝、肺、肾、大肠经,具凉血止血、清热解毒、消肿敛疮之功效;红花性温,味辛,归心、肝经,具活血通径、散瘀止痛之功效,与大蓟、穿山甲、蓖麻子、地榆共为佐药,发挥散瘀、活血、凉血、消肿拔毒、止痛作用;冰片性凉、味辛苦,归心、肺经,具通诸窍、散郁火、去翳明目、消肿止痛之功效,其香走窜,深入腠理,渗透力强,能促进药物有效成分的吸收,长时间作用于患处达到透皮作用为使药。
以上九味药配合应用,共奏清热解毒、祛腐生肌、活血化瘀、温经通络、消肿止痛之功效,对神经病变型、动脉缺血型、混合型糖尿病足,症见足部肌肉萎缩,足畸形,足部皮肤感染化脓、皲裂、溃疡,指端溃疡、坏疽等均有效。
本发明具有下述优点:
本发明根据传统中医理论选用选用全蝎、密陀僧、蜈蚣、冰片、大蓟、穿山甲、蓖麻子、地榆、红花为原料,原料易得且成本低,通过各味药材协同发挥清热解毒、祛腐生肌、活血化瘀、温经通络、消肿止痛的作用,用于治疗神经病变型、动脉缺血型、混合型糖尿病足,症见足部肌肉萎缩,足畸形,足部皮肤感染化脓、皲裂、溃疡,指端溃疡、坏疽,标本兼治,且无毒副作用,患者使用后不易复发,避免了西药治疗糖尿病足产生的副作用和截肢带来的巨大痛苦。
具体实施方式
实施例1
称取密陀僧30g,蜈蚣30g,冰片20g,大蓟20g,穿山甲20g,蓖麻子20g,地榆20g,红花20g,分别粉碎,研成粉末;将上述粉末混合,加入蛤蟆油60g,搅拌均匀即得外用膏剂。
实施例2
称取密陀僧20g,蜈蚣20g,冰片15g,大蓟15g,穿山甲15g,蓖麻子15g,地榆15g,红花15g,分别粉碎,研成粉末;将上述粉末混合,加入凡士林油45g,搅拌均匀即得外用膏剂。
实施例3
称取密陀僧10g,蜈蚣10g,冰片10g,大蓟10g,穿山甲10g,蓖麻子10g,地榆10g,红花10g,分别粉碎,研成粉末;将上述粉末混合,加入獾油30g,搅拌均匀即得外用膏剂。
实施例4
称取密陀僧10g,蜈蚣10g,冰片8g,大蓟8g,穿山甲8g,蓖麻子8g,地榆8g,红花8g,分别粉碎,研成粉末;将上述粉末混合,装入胶囊,即制得胶囊剂。
实施例5
称取密陀僧25g,蜈蚣25g,冰片20g,大蓟20g,穿山甲20g,蓖麻子20g,地榆20g,红花20g,分别粉碎,研成粉末;将上述粉末混合,加入獾油30g和蛤蟆油30g,搅拌均匀即得外用膏剂。
实施例6
称取密陀僧20g,蜈蚣20g,冰片15g,大蓟15g,穿山甲15g,蓖麻子15g,地榆15g,红花15g,分别粉碎,研成粉末;将上述粉末混合,加入蛤蟆油20g和凡士林20g,搅拌均匀即得外用膏剂。
实施例7
称取密陀僧15g,蜈蚣15g,冰片15g,大蓟15g,穿山甲15g,蓖麻子15g,地榆15g,红花15g,分别粉碎,研成粉末;将上述粉末混合,加入凡士林20g、蛤蟆油10g和獾油10g,搅拌均匀即得外用膏剂。
实验例
为了表明该中药组合物对神经病变型、动脉缺血型、混合型糖尿病足的治疗效果,本发明经100例系统临床观察,并记录其病史、病情、年龄及原始治疗方法进行对比疗效实验。
该100例患者中患有神经病变型糖尿病足30人、动脉缺血型糖尿病足40人、混合型糖尿病足30人。在上述患者中,大多数表现为足部肌肉萎缩,足畸形,足部皮肤感染化脓、皲裂、溃疡,指端溃疡、坏疽。
临床治疗效果的判断标准为:
临床治愈:原有症状消失。
显效:原有症状部分消失。
好转:原有病情有所减轻。
无效:症状体征无变化。
给药方法为:给患者患部贴敷实施例3制备的膏剂。
疗程:十五天为一疗程,每天使用一次。
临床实验结果表明,仅使用一疗程该中药组合物,原有症状明显减轻。据统计,5%症状较轻患者,可一次治愈,使用一疗程后,达到95%的治愈率,5%显效或好转,无无效情况(见表1)。
在上述临床实验中,对患者用药前后的血尿常规、肝肾功能、心电图等做了检查并记录,对比未发现异常,可见该中药组合物无毒副作用,两年后对上述病例进行回访,无复发患者。
对比实验例
称取39.6g人参、72.6g水蛭、46.2g土鳖虫、13.2g乳香(制)、33g赤芍、13.2g降香、13.2g檀香、19.8g全蝎、46.2g蝉蜕、6.6g蜈蚣、33g冰片、33g酸枣仁(炒),按照前述中国专利文献CN101757152A公开的方法制成胶囊。使用该胶囊对相同体质、病情状态的100例患者进行临床试用,给药方法为一次4粒,一日3次。
连续服用15天后,结果如表2所示,其平均治愈率只能达到30%,且仅对动脉缺血型糖尿病足疗效较好。
虽然本发明已经通过上述具体实施例对其进行了详细阐述,但是,本专业普通技术人员应该明白,在此基础上所做出的未超出权利要求保护范围的任何形式和细节的变化,均属于本发明所要保护的范围。
Claims (7)
1.一种中药组合物,其特征在于:该组合物原料药的重量份为:全蝎1-30份,密陀僧1-30份,蜈蚣1-30份,冰片1-20份,大蓟1-20份,穿山甲1-20份,蓖麻子1-20份,地榆1-20份,红花1-20份。
2.根据权利要求1所述的中药组合物,其特征在于:所述原料药的重量份为:全蝎2-20份,密陀僧2-20份,蜈蚣2-20份,冰片2-10份,大蓟2-10份,穿山甲2-10份,蓖麻子2-10份,地榆2-10份,红花2-10份。
3.根据权利要求2所述的中药组合物,其特征在于:所述原料药的重量份为:全蝎1份,密陀僧1份,蜈蚣1份,冰片1份,大蓟1份,穿山甲1份,蓖麻子1份,地榆1份,红花1份。
4.根据权利要求1至3任一所述的中药组合物,其特征在于:所述中药组合物可制成丸剂、片剂、胶囊剂、糖浆剂、颗粒剂、膏剂。
5.根据权利要求4所述的中药组合物,其特征在于:所述中药组合物制成膏剂时所选用的基质是蛤蟆油、凡士林、獾油中的一种或多种。
6.权利要求5所述的中药组合物的制备方法,包括如下步骤:
a)称取特定重量份的各原料药待用;
b)将全蝎、密陀僧、蜈蚣、冰片、大蓟、穿山甲、蓖麻子、地榆、红花分别粉碎,研成粉末;
c)将上述粉末混合,加入蛤蟆油、凡士林、獾油中的一种或多种,搅拌均匀即得外用膏剂。
7.权利要求1至3任一所述中药组合物在制备治疗糖尿病足药物中的用途。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012100173514A CN102552479B (zh) | 2012-01-19 | 2012-01-19 | 一种用于治疗糖尿病足的中药组合物 |
PCT/CN2012/084295 WO2013107206A1 (zh) | 2012-01-19 | 2012-11-08 | 一种用于治疗糖尿病足的中药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012100173514A CN102552479B (zh) | 2012-01-19 | 2012-01-19 | 一种用于治疗糖尿病足的中药组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102552479A true CN102552479A (zh) | 2012-07-11 |
CN102552479B CN102552479B (zh) | 2013-12-04 |
Family
ID=46399934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2012100173514A Expired - Fee Related CN102552479B (zh) | 2012-01-19 | 2012-01-19 | 一种用于治疗糖尿病足的中药组合物 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN102552479B (zh) |
WO (1) | WO2013107206A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103007089A (zh) * | 2013-01-11 | 2013-04-03 | 牟淑善 | 一种治疗颅脑外伤后并发应激性溃疡的中药组合物 |
WO2013107206A1 (zh) * | 2012-01-19 | 2013-07-25 | Sun Wankui | 一种用于治疗糖尿病足的中药组合物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1238984A (zh) * | 1999-06-15 | 1999-12-22 | 杨世伟 | 一种治疗面神经麻痹的药物及其制备方法 |
CN101229221A (zh) * | 2008-01-04 | 2008-07-30 | 张锡贵 | 一种治疗血栓闭塞脉管炎的中药及其制备方法 |
JP2009500367A (ja) * | 2005-07-07 | 2009-01-08 | フィディア ファルマチェウティチ ソシエタ ペル アチオニ | 創傷、火傷及び潰瘍の局所的治療のためのヒアルロン酸及びコラーゲナーゼを含有する新規医薬組成物 |
CN102119975A (zh) * | 2011-03-07 | 2011-07-13 | 李仲甫 | 一种治疗溃疡和褥疮及血管炎性感染性皮肤病的中草药药膏 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102552479B (zh) * | 2012-01-19 | 2013-12-04 | 孙万奎 | 一种用于治疗糖尿病足的中药组合物 |
-
2012
- 2012-01-19 CN CN2012100173514A patent/CN102552479B/zh not_active Expired - Fee Related
- 2012-11-08 WO PCT/CN2012/084295 patent/WO2013107206A1/zh active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1238984A (zh) * | 1999-06-15 | 1999-12-22 | 杨世伟 | 一种治疗面神经麻痹的药物及其制备方法 |
JP2009500367A (ja) * | 2005-07-07 | 2009-01-08 | フィディア ファルマチェウティチ ソシエタ ペル アチオニ | 創傷、火傷及び潰瘍の局所的治療のためのヒアルロン酸及びコラーゲナーゼを含有する新規医薬組成物 |
CN101229221A (zh) * | 2008-01-04 | 2008-07-30 | 张锡贵 | 一种治疗血栓闭塞脉管炎的中药及其制备方法 |
CN102119975A (zh) * | 2011-03-07 | 2011-07-13 | 李仲甫 | 一种治疗溃疡和褥疮及血管炎性感染性皮肤病的中草药药膏 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013107206A1 (zh) * | 2012-01-19 | 2013-07-25 | Sun Wankui | 一种用于治疗糖尿病足的中药组合物 |
CN103007089A (zh) * | 2013-01-11 | 2013-04-03 | 牟淑善 | 一种治疗颅脑外伤后并发应激性溃疡的中药组合物 |
CN103007089B (zh) * | 2013-01-11 | 2014-05-14 | 牟淑善 | 一种治疗颅脑外伤后并发应激性溃疡的中药组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN102552479B (zh) | 2013-12-04 |
WO2013107206A1 (zh) | 2013-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102319327A (zh) | 内外兼治治疗糖尿病足的中药 | |
CN104208245B (zh) | 手足癣中药药浴及制备方法 | |
CN102228485A (zh) | 用于烧伤康复的组合物及其制备方法 | |
CN101757333A (zh) | 一种治疗关节痛的外用中药制剂 | |
CN103550685B (zh) | 一种治疗腰腿痛的中药组合物 | |
CN108175795A (zh) | 一种膏药 | |
CN102100754A (zh) | 一种治疗骨质增生的中药组合物 | |
CN104258278A (zh) | 骨伤灵喷雾剂 | |
CN103463580B (zh) | 治疗经筋、骨、关节疼痛的中药膏及其制备方法 | |
CN102274252A (zh) | 治疗类风湿病的野木瓜外用制剂及其制备方法 | |
CN102552479B (zh) | 一种用于治疗糖尿病足的中药组合物 | |
CN103340933B (zh) | 一种中药组合物及在动脉粥样硬化治疗中的应用 | |
CN102988564B (zh) | 一种治疗日晒疮的中药组合物 | |
CN101804108B (zh) | 一种治疗神经性头痛的中药组合物 | |
CN103721067B (zh) | 一种糖尿病足护理中药组合物 | |
CN102614464A (zh) | 一种治疗糖尿病足的中药组合物 | |
CN105561270A (zh) | 一种外敷止痛中草药及其制备方法 | |
CN101804179B (zh) | 一种治疗颈椎腰椎骨质增生的中药组合物及其制备方法 | |
CN101507804B (zh) | 一种伤痛药及其制备工艺 | |
CN101884735B (zh) | 一种治疗血脂异常的药物及其制备方法 | |
CN101912566B (zh) | 治疗心悸的中药 | |
CN105560537A (zh) | 一种治疗骨性关节病的药物组合物及其制备方法 | |
CN101513509A (zh) | 一种缓解癌症症状的药物及其制备方法 | |
CN105617214A (zh) | 一种治疗疥疮的中药组合物 | |
CN105596783A (zh) | 外敷用中药膏贴及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20131204 |
|
CF01 | Termination of patent right due to non-payment of annual fee |